Percutaneous spinal fusion using bone morphogenetic protein-2 gene therapy

Tord D. Alden, Debra D. Pittman, Elisa J. Beres, Gerald R. Hankins, David F. Kallmes, Benjamin M. Wisotsky, Kelvin M. Kerns, Gregory A. Helm

Research output: Contribution to journalArticle

113 Scopus citations

Abstract

Object. Gene therapy has many potential applications in neurosurgery. One application involves bone morphogenetic protein-2 (BMP-2), a low- molecular-weight glycoprotein that induces bone formation in vivo. Numerous studies have demonstrated that the BMP-2 protein can enhance spinal fusion. This study was undertaken to determine whether direct injection of an adenoviral construct containing the BMP-2 gene can be used for spinal fusion. Methods. Twelve athymic nude rats were used in this study. Recombinant, replication-defective type 5 adenovirus with the cytomegalovirus (CMV) promoter and BMP-2 gene (Ad-BMP-2) was used. A second adenovirus constructed with the CMV promoter and β-galactosidase (β-gal) gene (Ad-β-gal) was used as a control. In three groups (four rats each) 7.5 μl of virus (5 X 108 particles/μl) was injected percutaneously and paraspinally at the lumbosacral junction: Group 1 received Ad-BMP-2 bilaterally; Group 2 received Ad-BMP-2 on the right, Ad-β-gal on the left; and Group 3 received Ad-β-gal bilaterally. Computerized tomography (CT) scans of the lumbosacral spine were obtained at 3, 5, 8, and 12 weeks. At 12 weeks, the animals were killed and underwent histological inspection. Ectopic bone formation was observed both on three-dimensionally reconstructed CT scans and histological examination in all rats at sites treated with Ad-BMP-2. Histological analysis demonstrated bone at different stages of maturity adjacent to the spinous processes, laminae, and transverse processes. Conclusions. Results of this study clearly demonstrated that it is possible to produce in vivo endochondral bone formation by using direct adenoviral construct injection into the paraspinal musculature, which suggests that gene therapy may be useful for spinal fusion in the future.

Original languageEnglish (US)
Pages (from-to)109-114
Number of pages6
JournalJournal of neurosurgery
Volume90
Issue number1 SUPPL.
StatePublished - Jan 1 1999

Keywords

  • Adenovirus
  • Animal model
  • Gene therapy
  • Percutaneous
  • Rat
  • Spinal fusion bone morphogenetic protein

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Percutaneous spinal fusion using bone morphogenetic protein-2 gene therapy'. Together they form a unique fingerprint.

  • Cite this

    Alden, T. D., Pittman, D. D., Beres, E. J., Hankins, G. R., Kallmes, D. F., Wisotsky, B. M., Kerns, K. M., & Helm, G. A. (1999). Percutaneous spinal fusion using bone morphogenetic protein-2 gene therapy. Journal of neurosurgery, 90(1 SUPPL.), 109-114.